Our ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of our innovative peptide technology.
Our focus is on applying our peptide technology across a wide range of indications through independent and partnered development pathways.
We’re looking for passionate, innovative individuals who can help us to deliver our technology to the people who need it most, and we’ve fostered a unique working culture to support this mission.
Introduction of PepGen’s novel enhanced delivery oligonucleotide platform and therapeutic development plans to the CureDuchenne Community BOSTON and OXFORD, United Kingdom, April 19, 2021 — PepGen, an emerging biotechnology company focused on developing transformative therapies for individuals living with neuromuscular and neurologic diseases, will present a webinar…
Boston, Mass. and Oxford, UK (March 23, 2021) – PepGen, Inc. a biotechnology company developing transformative therapies for individuals living with neuromuscular and neurologic diseases, today announced that Dr. James McArthur, CEO, will present at Stifel’s 3rd Annual CNS Day virtual conference. The presentation is scheduled for Wednesday, March 31,…
EDO platform demonstrates potentially best-in-class safety and efficacy profile in addressing DMD and DM1 disease phenotypes; advancing rapidly to the clinic with first-in-human studies expected to initiate in early 2022 Boston, Mass. and Oxford, UK (March 15, 2021) – PepGen, an emerging biotechnology company focused on developing transformative therapies for…
